NeoGenomics Net Debt To E B I T D A from 2010 to 2024

NEO Stock  USD 17.18  0.25  1.48%   
NeoGenomics Net Debt To EBITDA yearly trend continues to be very stable with very little volatility. Net Debt To EBITDA is likely to grow to -14.52 this year. Net Debt To EBITDA is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). View All Fundamentals
 
Net Debt To EBITDA  
First Reported
2010-12-31
Previous Quarter
(15.29)
Current Value
(14.52)
Quarterly Volatility
7.29908281
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NeoGenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoGenomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 76.2 M, Interest Expense of 7.3 M or Selling General Administrative of 255.3 M, as well as many indicators such as Price To Sales Ratio of 3.26, Dividend Yield of 0.0 or PTB Ratio of 2.05. NeoGenomics financial statements analysis is a perfect complement when working with NeoGenomics Valuation or Volatility modules.
  
Check out the analysis of NeoGenomics Correlation against competitors.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

Latest NeoGenomics' Net Debt To E B I T D A Growth Pattern

Below is the plot of the Net Debt To E B I T D A of NeoGenomics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). NeoGenomics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeoGenomics' overall financial position and show how it may be relating to other accounts over time.
Net Debt To E B I T D A10 Years Trend
Slightly volatile
   Net Debt To E B I T D A   
       Timeline  

NeoGenomics Net Debt To E B I T D A Regression Statistics

Arithmetic Mean(0.20)
Coefficient Of Variation(3,578)
Mean Deviation5.01
Median0.73
Standard Deviation7.30
Sample Variance53.28
Range28.9641
R-Value(0.54)
Mean Square Error40.60
R-Squared0.29
Significance0.04
Slope(0.88)
Total Sum of Squares745.87

NeoGenomics Net Debt To E B I T D A History

2024 -14.52
2023 -15.29
2022 -4.42
2021 5.68
2020 -0.3
2019 -0.93
2018 3.22

About NeoGenomics Financial Statements

NeoGenomics investors utilize fundamental indicators, such as Net Debt To E B I T D A, to predict how NeoGenomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt To EBITDA(15.29)(14.52)

Pair Trading with NeoGenomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.

Moving against NeoGenomics Stock

  0.85HCM HUTCHMED DRCPairCorr
  0.82FLGC Flora Growth CorpPairCorr
  0.59AQB AquaBounty TechnologiesPairCorr
  0.57EXAS EXACT Sciences Upward RallyPairCorr
  0.55VRDN Viridian Therapeutics Buyout TrendPairCorr
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out the analysis of NeoGenomics Correlation against competitors.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.